{"id":"switch-to-a-second-anti-tnf-drug-alone","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (including serious infections)"},{"rate":null,"effect":"Tuberculosis reactivation"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Autoimmune phenomena (lupus-like syndrome)"},{"rate":null,"effect":"Hematologic abnormalities"}]},"_chembl":{"chemblId":"CHEMBL3897557","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This represents a clinical strategy rather than a single drug entity. Anti-TNF agents work by blocking tumor necrosis factor-alpha, a key inflammatory cytokine. Switching between different anti-TNF drugs (e.g., from infliximab to adalimumab, or etanercept to golimumab) may be employed when patients lose response to the first agent due to immunogenicity, loss of efficacy, or intolerance, allowing continued TNF pathway inhibition with a structurally different molecule.","oneSentence":"Switching to a second anti-TNF agent involves discontinuing one TNF inhibitor and initiating a different TNF inhibitor to maintain or restore therapeutic response in inflammatory conditions.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:38:16.698Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"},{"name":"Inflammatory bowel disease (Crohn's disease, ulcerative colitis)"},{"name":"Psoriasis"}]},"trialDetails":[{"nctId":"NCT03580876","phase":"PHASE4","title":"Addition of Azathioprine in IBD Patients With Immunogenic Failure","status":"UNKNOWN","sponsor":"Védrines, Philippe, M.D.","startDate":"2018-07-23","conditions":"Clinical Failure After Switch","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Switch to a second anti-TNF drug alone","genericName":"Switch to a second anti-TNF drug alone","companyName":"Védrines, Philippe, M.D.","companyId":"v-drines-philippe-m-d","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Switching to a second anti-TNF agent involves discontinuing one TNF inhibitor and initiating a different TNF inhibitor to maintain or restore therapeutic response in inflammatory conditions. Used for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}